{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T14:01:44Z","timestamp":1708005704001},"reference-count":11,"publisher":"Georg Thieme Verlag KG","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,9]]},"abstract":"Zusammenfassung<\/jats:title>\n Anamnese\u2002Bei einem 79-j\u00e4hrigen wurde eine HFrEF (heart failure with reduced ejection fraction) mit einer linksventrikul\u00e4ren Ejektionsfraktion von 25\u201330\u200a% nachgewiesen. Zur weiteren Behandlung wurde eine kardiologische Rehabilitationsma\u00dfnahme durchgef\u00fchrt.<\/jats:p>\n Klinischer Befund\u2002Bei Antritt der AHB klagte der Patient \u00fcber Luftnot bei geringer Belastung entsprechend dem Stadium NYHA III. Die medikament\u00f6se Therapie beinhaltete Empagliflozin 10\u200amg, Sacubitril\/Valsartan 24\/26\u200amg, Edoxaban 60\u200amg, Torasemid 5\u200amg, Verapamil 80\u200amg sowie Amiodaron 200\u200amg.<\/jats:p>\n Untersuchungen\u2002Im Blutzucker-Tagesprofil zeigten sich Hypoglyk\u00e4mien mit Werten <\u200a3,7\u200ammol\/l (<\u200a67\u200amg\/dl). Nach R\u00fccksprache mit dem Patienten traten diese unter normaler Nahrungsaufnahme auf und waren in Form von Schwindel im Zeitraum der Hypoglyk\u00e4mien symptomatisch.<\/jats:p>\n Diagnose\u2002Symptomatische Hypoglyk\u00e4mie unter SGLT2(sodium-glucose linked transporter 2)-Inhibitor-Therapie bei einem Patienten mit HFrEF ohne Diabetes mellitus.<\/jats:p>\n Therapie und Verlauf\u2002Die Therapie mit Empagliflozin wurde beendet und ein erneutes Blutzucker-Tagesprofil durchgef\u00fchrt \u2013 dieses zeigte keine hypoglyk\u00e4mischen Werte mehr.<\/jats:p>\n Folgerung\u2002Der hier vorgestellte Fall sensibilisiert f\u00fcr die unter SGLT2-Inhibitoren in Studien sehr selten auftretende Nebenwirkung der Hypoglyk\u00e4mie bei Patienten mit HFrEF ohne Vorliegen eines Diabetes mellitus.<\/jats:p>","DOI":"10.1055\/a-1892-4104","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T22:34:24Z","timestamp":1662590064000},"page":"1195-1198","source":"Crossref","is-referenced-by-count":2,"title":["Hypoglyk\u00e4mie unter SGLT2-Inhibition bei einem Patienten mit HFrEF ohne Diabetes mellitus"],"prefix":"10.1055","volume":"147","author":[{"given":"Hendrik","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie und Diabetologie, Klinikum Magdeburg"},{"name":"Medizinische Fakult\u00e4t der Martin-Luther-Universit\u00e4t Halle-Wittenberg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schlitt","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t der Martin-Luther-Universit\u00e4t Halle-Wittenberg"},{"name":"Abteilung f\u00fcr Kardiologie und Diabetologie, Paracelsus-Harz-Klinik Bad Suderode"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"A L Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"T A McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"S D Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis","volume":"21","author":"T Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"G L Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"J JV McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"M Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"H JL Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"S D Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial","volume":"143","author":"S D Anker","year":"2021","journal-title":"Circulation"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1892-4104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T22:35:40Z","timestamp":1662590140000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1892-4104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":11,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9,7]]},"published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1892-4104","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}